Boston Family Office LLC Has $4.12 Million Holdings in Pfizer Inc. (PFE)

Boston Family Office LLC grew its position in shares of Pfizer Inc. (NYSE:PFE) by 0.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 122,674 shares of the biopharmaceutical company’s stock after acquiring an additional 290 shares during the quarter. Boston Family Office LLC’s holdings in Pfizer were worth $4,121,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Marshall Wace North America L.P. boosted its holdings in Pfizer by 142.8% during the 2nd quarter. Marshall Wace North America L.P. now owns 4,229,547 shares of the biopharmaceutical company’s stock worth $143,805,000 after acquiring an additional 2,487,663 shares during the last quarter. Investment Management of Virginia LLC boosted its holdings in shares of Pfizer by 0.4% in the 2nd quarter. Investment Management of Virginia LLC now owns 78,729 shares of the biopharmaceutical company’s stock worth $2,645,000 after buying an additional 302 shares during the last quarter. Annex Advisory Services LLC boosted its holdings in shares of Pfizer by 11.3% in the 2nd quarter. Annex Advisory Services LLC now owns 35,187 shares of the biopharmaceutical company’s stock worth $1,182,000 after buying an additional 3,576 shares during the last quarter. ARS Investment Partners LLC boosted its holdings in shares of Pfizer by 0.9% in the 2nd quarter. ARS Investment Partners LLC now owns 390,404 shares of the biopharmaceutical company’s stock worth $13,114,000 after buying an additional 3,494 shares during the last quarter. Finally, Loudon Investment Management LLC boosted its holdings in shares of Pfizer by 5.4% in the 2nd quarter. Loudon Investment Management LLC now owns 50,193 shares of the biopharmaceutical company’s stock worth $1,686,000 after buying an additional 2,577 shares during the last quarter. 69.34% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages recently weighed in on PFE. Jefferies Group LLC set a $35.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a report on Wednesday, August 2nd. BMO Capital Markets set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Saturday. Berenberg Bank set a $39.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a report on Tuesday, August 1st. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a report on Tuesday, October 3rd. Finally, Vetr downgraded shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price target on the stock. in a report on Wednesday, September 13th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $38.66.

In other Pfizer news, EVP Frank A. Damelio sold 94,409 shares of the company’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $3,209,906.00. Following the sale, the executive vice president now directly owns 337,389 shares of the company’s stock, valued at $11,471,226. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Ian C. Read sold 197,168 shares of the company’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $6,703,712.00. Following the sale, the chief executive officer now directly owns 580,318 shares in the company, valued at $19,730,812. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 366,557 shares of company stock worth $12,532,406. Insiders own 0.06% of the company’s stock.

Pfizer Inc. (PFE) traded up $0.05 during midday trading on Friday, reaching $35.49. 6,400,000 shares of the company’s stock traded hands, compared to its average volume of 14,047,984. The stock has a market capitalization of $211,545.50, a P/E ratio of 14.20, a PEG ratio of 2.51 and a beta of 1.01. Pfizer Inc. has a 1-year low of $30.51 and a 1-year high of $36.78. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The company’s revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.61 earnings per share. equities research analysts expect that Pfizer Inc. will post 2.6 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 3.61%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is presently 79.01%.

TRADEMARK VIOLATION NOTICE: This report was reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://transcriptdaily.com/2017/11/26/boston-family-office-llc-has-4-12-million-holdings-in-pfizer-inc-pfe.html.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply